OtherBASIC SCIENCE INVESTIGATIONS

Evidence that Myocardial Na/I Symporter Gene Imaging Does Not Perturb Cardiac Function

Kyung-Han Lee, Jun-Sang Bae, Sang-Chul Lee, Jin-Young Paik, Takashi Matsui, Kyung-Ho Jung, Bong-Ho Ko and Byung-Tae Kim
Journal of Nuclear Medicine November 2006, 47 (11) 1851-1857;

Article Figures & Data

Figures

  • FIGURE 1. 
    FIGURE 1. 

    Effect of adenoviral gene transfer and 123I treatment on cultured cardiac cells. (A) Number of viable cells at 4 and 9 d after infection with 10 MOIs of Ad.EGFP or Ad.EGFP.NIS and in uninfected controls. Cells were incubated with 0 or 185 kBq (0 or 0.5 μCi) 123I for 6 h at days 4 and 9. (B) MTT assay results of cells treated as in A. Cells are H9C2 myoblasts differentiated into cardiomyocytes by stimulation with retinoic acid. All results are mean ± SD of 4 samples obtained from a single experiment (representative of 2 experiments).

  • FIGURE 2. 
    FIGURE 2. 

    Time course of cardiac 123I uptake. (A) Serial scintigraphic rat images at 2, 4, and 9 d after myocardial injection with 3 × 108 pfu of Ad.EGFP.NIS (n = 5). Arrow denotes focal cardiac 123I uptake consistent with site of adenovirus injection. (B) Semiquantitative C/M ratios expressed as mean ± SE of values obtained from 5 animals.

  • FIGURE 3. 
    FIGURE 3. 

    Serum CK and myocardial MPO activity. (A) Total serum CK activity (mean ± SE; IU/L) at 3 (D3), 7 (D7), and 14 (D14) d after myocardial injection of Ad.EGFP.NIS (n = 3) or Ad.EGFP (n = 3), in negative controls (n = 3), and at 3 d of ischemia–reperfusion (n = 4). (B) Myocardial MPO activity (mean ± SE; U/g) in rats as in A (14 d after adenovirus injection). NS = not significant.

  • FIGURE 4. 
    FIGURE 4. 

    Hematoxylin-stained myocardial microsections obtained 14 d after intramyocardial injection of Ad.EGFP.NIS (A and B) or Ad.EGFP (C and D). Arrows indicate areas of localized inflammatory infiltration, consistent with injection site. Length of bar indicates 400 μm for A and C and 100 μm for B and D.

Tables

  • TABLE 1

    Echocardiographic Measurements Before and Serially After Intramyocardial Ad.EGFP or Ad.EGFP.NIS Injection

    Ad.EGFPAd.EGFP.NIS
    MeasurementBaselineDay 4Day 9BaselineDay 4Day 9
    Heart rate (bpm)341 ± 40328 ± 63306 ± 42300 ± 29292 ± 33318 ± 52
    LV dimension
     IVS thickness (mm)1.5 ± 0.41.6 ± 0.31.7 ± 0.31.6 ± 0.41.8 ± 0.61.8 ± 0.3
     PW thickness (mm)1.8 ± 0.11.8 ± 0.21.7 ± 0.21.7 ± 0.31.6 ± 0.21.8 ± 0.3
     Diastolic diameter (mm)6.8 ± 0.66.8 ± 0.97.5 ± 1.06.9 ± 0.86.8 ± 0.67.5 ± 0.9
     Systolic diameter (mm)3.1 ± 0.83.7 ± 1.04.2 ± 0.7*3.1 ± 0.93.3 ± 0.84.4 ± 0.8*
     IVS/LVPW ratio0.9 ± 0.10.9 ± 0.11.0 ± 0.21.0 ± 0.21.1 ± 0.31.0 ± 0.2
     Diastolic volume (mL)0.7 ± 0.20.7 ± 0.31.0 ± 0.3†0.7 ± 0.20.7 ± 0.21.0 ± 0.3†
     Systolic volume (mL)0.1 ± 0.00.2 ± 0.10.2 ± 0.1*0.1 ± 0.10.1 ± 0.10.2 ± 0.1†
     LV mass (g)0.7 ± 0.10.8 ± 0.20.9 ± 0.2†0.7 ± 0.10.8 ± 0.21.0 ± 0.2‡
    LV functional parameter
     LV FS (%)54.7 ± 10.046.7 ± 7.6†43.6 ± 4.9‡54.3 ± 9.148.6 ± 5.042.4 ± 4.7*
     LV EF (%)88.2 ± 6.482.3 ± 7.779.6 ± 5.0*88.0 ± 5.486.5 ± 5.778.7 ± 4.6*

    • ↵* P < 0.005 compared with baseline measurements.

    • ↵† P < 0.05 compared with baseline measurements.

    • ↵‡ P < 0.01 compared with baseline measurements.

    • IVS = interventricular septum; PW = posterior wall; LVPW = LV posterior wall; LVFS = LV fractional shortening.

    • Data are mean ± SD.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section